320 related articles for article (PubMed ID: 33792453)
1. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
[TBL] [Abstract][Full Text] [Related]
2. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
[TBL] [Abstract][Full Text] [Related]
3. Zilucoplan: First Approval.
Shirley M
Drugs; 2024 Jan; 84(1):99-104. PubMed ID: 38093160
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF; Bresch S; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Lowcock R; Vanderkelen M; Leite MI;
Lancet Neurol; 2023 May; 22(5):395-406. PubMed ID: 37059508
[TBL] [Abstract][Full Text] [Related]
5. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
6. Complement Inhibitor Therapy for Myasthenia Gravis.
Albazli K; Kaminski HJ; Howard JF
Front Immunol; 2020; 11():917. PubMed ID: 32582144
[TBL] [Abstract][Full Text] [Related]
7. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
Beecher G; Putko BN; Wagner AN; Siddiqi ZA
Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.
Howard JF; Bresch S; Farmakidis C; Freimer M; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Nowak RJ; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Bloemers J; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Vanderkelen M; Leite MI;
Ther Adv Neurol Disord; 2024; 17():17562864241243186. PubMed ID: 38638673
[TBL] [Abstract][Full Text] [Related]
9. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
12. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan.
Gorman DM; Lee J; Payne CD; Woodruff TM; Clark RJ
Amino Acids; 2021 Jan; 53(1):143-147. PubMed ID: 33398524
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab for the treatment of myasthenia gravis.
Mantegazza R; Cavalcante P
Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
[TBL] [Abstract][Full Text] [Related]
14. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
Vu T; Ortiz S; Katsuno M; Annane D; Mantegazza R; Beasley KN; Aguzzi R; Howard JF
J Neurol; 2023 Jun; 270(6):3129-3137. PubMed ID: 36890354
[TBL] [Abstract][Full Text] [Related]
15. Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ; Tang Y; Dhamnaskar K; Hoarty MD; Vyasamneni R; Vadysirisack DD; Ma Z; Zhu N; Wang JG; Bu C; Cong B; Palmer E; Duda PW; Sayegh C; Ricardo A
Front Immunol; 2023; 14():1213920. PubMed ID: 37622108
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab: A Review in Generalized Myasthenia Gravis.
Dhillon S
Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
[TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
Xiao H; Wu K; Liang X; Li R; Lai KP
Front Immunol; 2021; 12():715036. PubMed ID: 34456922
[TBL] [Abstract][Full Text] [Related]
18. Role of complement in myasthenia gravis.
San PP; Jacob S
Front Neurol; 2023; 14():1277596. PubMed ID: 37869140
[TBL] [Abstract][Full Text] [Related]
19. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
